Open Access

, volume 106 , issue 6 , pages 1599-1607

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades

Jason P. Cooper, Barry E. Storer, Noa Granot, Boglark Gyurkocza, Mohamed L. Sorror, Thomas R. Chauncey, Judith Shizuru, Georg-Nikolaus Franke, Michael B. Maris, Michael Boyer, Benedetto Bruno, Firoozeh Sahebi, Amelia A. Langston, Parameswaran Hari, Edward D. Agura, Søren Lykke Petersen, Richard T. Maziarz, Wolfgang Bethge, Julie Asch, Jonathan A. Gutman, Gitte Olesen, Andrew M. Yeager, Kai Hübel, William J. Hogan, David G. Maloney, Marco Mielcarek, Paul J. Martin, Mary E.D. Flowers, George E. Georges, Ann E. Woolfrey, H. Joachim Deeg, Bart L. Scott, George B. McDonald, Rainer Storb, Brenda M. Sandmaier

Publication type: Journal Article

Publication date: 2020-06-04

Ferrata Storti Foundation

Haematologica

scimago Q1

wos Q1

SJR: 2.449

CiteScore: 11.3

Impact factor: 7.9

ISSN: 03906078, 15928721

DOI: 10.3324/haematol.2020.248187

Copy DOI

PubMed ID: 32499241

Hematology

Abstract

We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997-2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation +/- fludarabine or clofarabine before transplantation from HLA-matched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997 +/- 2003 (n=562), 2004 +/- 2009 (n=594), and 2010 +/- 2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997 +/- 2003 to 56% in 2010–2017, and with scores from the Hematopoietic Cell Transplantation Comborbidity Index of ≥3 increased from 25% in 1997 +/- 2003 to 45% in 2010 +/- 2017. Use of unrelated donors increased from 34% in 1997 +/- 2003 to 65% in 2010–2017. When outcomes from 2004 +/- 2009 and 2010–2017 were compared to 1997 +/- 2003, improvements were noted in overall survival (P=.0001 for 2004–2009 and P <.0001 for 2010–2017), profression-free survival (P=.002 for 2004–2009 and P <.0001 for 2010 +/- 2017), non-relapse mortality (P<.0001 for 2004 +/- 2009 and P <.0001 for 2010 +/- 2017), and in rates of grades 2 +/- 4 acute and chronic graft-vs.-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under ClinicalTrials.gov identifiers: NCT00003145, NCT00003196, NCT00003954, NCT00005799, NCT00005801, NCT00005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045.

Found

Top-30

Journals

	1 2 3 4
Cancers	Cancers, 4, 14.81% Cancers 4 publications, 14.81%
European Journal of Oncology Nursing	European Journal of Oncology Nursing, 2, 7.41% European Journal of Oncology Nursing 2 publications, 7.41%
Transplantation and Cellular Therapy	Transplantation and Cellular Therapy, 2, 7.41% Transplantation and Cellular Therapy 2 publications, 7.41%
HemaSphere	HemaSphere, 1, 3.7% HemaSphere 1 publication, 3.7%
Expert Review of Hematology	Expert Review of Hematology, 1, 3.7% Expert Review of Hematology 1 publication, 3.7%
Frontiers in Endocrinology	Frontiers in Endocrinology, 1, 3.7% Frontiers in Endocrinology 1 publication, 3.7%
Strahlentherapie und Onkologie	Strahlentherapie und Onkologie, 1, 3.7% Strahlentherapie und Onkologie 1 publication, 3.7%
Bone Marrow Transplantation	Bone Marrow Transplantation, 1, 3.7% Bone Marrow Transplantation 1 publication, 3.7%
Leukemia	Leukemia, 1, 3.7% Leukemia 1 publication, 3.7%
Seminars in Nuclear Medicine	Seminars in Nuclear Medicine, 1, 3.7% Seminars in Nuclear Medicine 1 publication, 3.7%
Frontiers in Immunology	Frontiers in Immunology, 1, 3.7% Frontiers in Immunology 1 publication, 3.7%
PLoS ONE	PLoS ONE, 1, 3.7% PLoS ONE 1 publication, 3.7%
Haematologica	Haematologica, 1, 3.7% Haematologica 1 publication, 3.7%
Signal Transduction and Targeted Therapy	Signal Transduction and Targeted Therapy, 1, 3.7% Signal Transduction and Targeted Therapy 1 publication, 3.7%
Stem Cell Research and Therapy	Stem Cell Research and Therapy, 1, 3.7% Stem Cell Research and Therapy 1 publication, 3.7%
Supportive Care in Cancer	Supportive Care in Cancer, 1, 3.7% Supportive Care in Cancer 1 publication, 3.7%
Journal of Thrombosis and Haemostasis	Journal of Thrombosis and Haemostasis, 1, 3.7% Journal of Thrombosis and Haemostasis 1 publication, 3.7%
Cytotherapy	Cytotherapy, 1, 3.7% Cytotherapy 1 publication, 3.7%
Blood Research	Blood Research, 1, 3.7% Blood Research 1 publication, 3.7%
British Journal of Haematology	British Journal of Haematology, 1, 3.7% British Journal of Haematology 1 publication, 3.7%
Current Oncology	Current Oncology, 1, 3.7% Current Oncology 1 publication, 3.7%
Blood advances	Blood advances, 1, 3.7% Blood advances 1 publication, 3.7%
	1 2 3 4

Publishers

	1 2 3 4 5 6 7
Springer Nature	Springer Nature, 7, 25.93% Springer Nature 7 publications, 25.93%
Elsevier	Elsevier, 7, 25.93% Elsevier 7 publications, 25.93%
MDPI	MDPI, 5, 18.52% MDPI 5 publications, 18.52%
Frontiers Media S.A.	Frontiers Media S.A., 2, 7.41% Frontiers Media S.A. 2 publications, 7.41%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 1, 3.7% Ovid Technologies (Wolters Kluwer Health) 1 publication, 3.7%
Taylor & Francis	Taylor & Francis, 1, 3.7% Taylor & Francis 1 publication, 3.7%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 3.7% Public Library of Science (PLoS) 1 publication, 3.7%
Ferrata Storti Foundation	Ferrata Storti Foundation, 1, 3.7% Ferrata Storti Foundation 1 publication, 3.7%
Wiley	Wiley, 1, 3.7% Wiley 1 publication, 3.7%
American Society of Hematology	American Society of Hematology, 1, 3.7% American Society of Hematology 1 publication, 3.7%
	1 2 3 4 5 6 7

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Jason P. et al. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades // Haematologica. 2020. Vol. 106. No. 6. pp. 1599-1607.

GOST all authors (up to 50) Copy

Jason P., Barry E., Noa G., Boglark G., Mohamed L., Thomas R., Judith S., Georg-Nikolaus F., Michael B., Michael B., Benedetto B., Firoozeh S., Amelia A., Parameswaran H., Edward D., Søren L., Richard T., Wolfgang B., Julie A., Jonathan A., Gitte O., Andrew M., Kai H., William J., David G., Marco M., Paul J., Mary E. D., George E., Ann E., H. J., Bart L., George B., Rainer S., Brenda M. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades // Haematologica. 2020. Vol. 106. No. 6. pp. 1599-1607.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.3324/haematol.2020.248187

UR - https://doi.org/10.3324/haematol.2020.248187

TI - Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades

T2 - Haematologica

AU - Jason, P

AU - Barry, E

AU - Noa, Granot

AU - Boglark, Gyurkocza

AU - Mohamed, L

AU - Thomas, R

AU - Judith, Shizuru

AU - Georg-Nikolaus, Franke

AU - Michael, B

AU - Michael, Boyer

AU - Benedetto, Bruno

AU - Firoozeh, Sahebi

AU - Amelia, A

AU - Parameswaran, Hari

AU - Edward, D

AU - Søren, Lykke

AU - Richard, T

AU - Wolfgang, Bethge

AU - Julie, Asch

AU - Jonathan, A

AU - Gitte, Olesen

AU - Andrew, M

AU - Kai, Hübel

AU - William, J

AU - David, G

AU - Marco, Mielcarek

AU - Paul, J

AU - Mary, E D

AU - George, E

AU - Ann, E

AU - H., Joachim

AU - Bart, L

AU - George, B

AU - Rainer, Storb

AU - Brenda, M

PY - 2020

DA - 2020/06/04

PB - Ferrata Storti Foundation

SP - 1599-1607

IS - 6

VL - 106

PMID - 32499241

SN - 0390-6078

SN - 1592-8721

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Jason,

author = {P Jason and E Barry and Granot Noa and Gyurkocza Boglark and L Mohamed and R Thomas and Shizuru Judith and Franke Georg-Nikolaus and B Michael and Boyer Michael and Bruno Benedetto and Sahebi Firoozeh and A Amelia and Hari Parameswaran and D Edward and Lykke Søren and T Richard and Bethge Wolfgang and Asch Julie and A Jonathan and Olesen Gitte and M Andrew and Hübel Kai and J William and G David and Mielcarek Marco and J Paul and E D Mary and E George and E Ann and Joachim H. and L Bart and B George and Storb Rainer and M Brenda},

title = {Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades},

journal = {Haematologica},

year = {2020},

volume = {106},

publisher = {Ferrata Storti Foundation},

month = {jun},

url = {https://doi.org/10.3324/haematol.2020.248187},

number = {6},

pages = {1599--1607},

doi = {10.3324/haematol.2020.248187}

}

MLA

Cite this

MLA Copy

Jason, P., et al. “Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.” Haematologica, vol. 106, no. 6, Jun. 2020, pp. 1599-1607. https://doi.org/10.3324/haematol.2020.248187.

Publisher

Ferrata Storti Foundation

Journal

Haematologica

scimago Q1

wos Q1

SJR

2.449

CiteScore

11.3

Impact factor

7.9

ISSN

03906078 (Print)

15928721 (Electronic)